1
|
Desai SJ, Bharne AP, Upadhya MA, Somalwar AR, Subhedar NK, Kokare DM. A simple and economical method of electrode fabrication for brain self-stimulation in rats. J Pharmacol Toxicol Methods 2014; 69:141-9. [DOI: 10.1016/j.vascn.2013.12.006] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/05/2013] [Revised: 12/18/2013] [Accepted: 12/20/2013] [Indexed: 12/01/2022]
|
2
|
Itasaka M, Hanasawa M, Hironaka N, Miyata H, Nakayama K. Facilitation of intracranial self-stimulation behavior in rats by environmental stimuli associated with nicotine. Physiol Behav 2012; 107:277-82. [DOI: 10.1016/j.physbeh.2012.09.006] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/09/2012] [Revised: 07/17/2012] [Accepted: 09/11/2012] [Indexed: 11/15/2022]
|
3
|
Wigestrand MB, Fonnum F, Ivar Walaas S. Subunit-specific modulation of [3H]MK-801 binding to NMDA receptors mediated by dopamine receptor ligands in rodent brain. Neurochem Int 2012; 61:266-76. [DOI: 10.1016/j.neuint.2012.04.017] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/04/2012] [Revised: 04/16/2012] [Accepted: 04/18/2012] [Indexed: 11/27/2022]
|
4
|
Waraczynski M, Salemme J, Farral B. Brain stimulation reward is affected by D2 dopamine receptor manipulations in the extended amygdala but not the nucleus accumbens. Behav Brain Res 2010; 208:626-35. [DOI: 10.1016/j.bbr.2010.01.009] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/12/2009] [Revised: 12/06/2009] [Accepted: 01/10/2010] [Indexed: 12/13/2022]
|
5
|
The neuropharmacological substrates of nicotine reward: reinforcing versus reinforcement-enhancing effects of nicotine. Behav Pharmacol 2009; 20:211-25. [PMID: 19421028 DOI: 10.1097/fbp.0b013e32832c7083] [Citation(s) in RCA: 25] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/31/2022]
Abstract
Compulsive nicotine use is thought to be maintained by the acute reinforcing effects of nicotine and the reinforcement-enhancing effects of nicotine, in addition to the negative consequences of nicotine abstinence. Nicotine self-administration and nicotine-induced enhancement of non-nicotine reinforcers such as intracranial self-stimulation provide measures of these dual rewarding properties of nicotine. First, pharmacological manipulations that modulate the reinforcing and reinforcement-enhancing effects of nicotine are identified and discussed. Second, the interpretation and implications of data that identified shared and specific pharmacological substrates underlying the dual rewarding effects of nicotine are discussed, including implications for the preclinical testing of putative antismoking medications. In conclusion, reinforcement-related behaviors that are mediated by central reinforcement processes are likely to, and generally do, exhibit a number of common pharmacological substrates. Interestingly, however, a few pharmacological classes of compounds seem to exert selective effects on components of the dual nicotine reward mechanisms, indicating differences in the pharmacological substrates of the reinforcing and reinforcement-enhancing effects of nicotine. Further characterization of such compounds may ultimately lead to the identification of novel medications for nicotine dependence in humans.
Collapse
|
6
|
Cheer JF, Aragona BJ, Heien MLAV, Seipel AT, Carelli RM, Wightman RM. Coordinated accumbal dopamine release and neural activity drive goal-directed behavior. Neuron 2007; 54:237-44. [PMID: 17442245 DOI: 10.1016/j.neuron.2007.03.021] [Citation(s) in RCA: 139] [Impact Index Per Article: 8.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/09/2006] [Revised: 02/13/2007] [Accepted: 03/26/2007] [Indexed: 10/23/2022]
Abstract
Intracranial self-stimulation (ICSS) activates the neural pathways that mediate reward, including dopaminergic terminal areas such as the nucleus accumbens (NAc). However, a direct role of dopamine in ICSS-mediated reward has been questioned. Here, simultaneous voltammetric and electrophysiological recordings from the same electrode reveal that, at certain sites, the onset of anticipatory dopamine surges and changes in neuronal firing patterns during ICSS are coincident, whereas sites lacking dopamine changes also lack patterned firing. Intrashell microinfusion of a D1, but not a D2 receptor antagonist, blocks ICSS. An iontophoresis approach was implemented to explore the effect of dopamine antagonists on firing patterns without altering behavior. Similar to the microinfusion experiments, ICSS-related firing is selectively attenuated following D1 receptor blockade. This work establishes a temporal link between anticipatory rises of dopamine and firing patterns in the NAc shell during ICSS and suggests that they may play a similar role with natural rewards and during drug self-administration.
Collapse
Affiliation(s)
- Joseph F Cheer
- Department of Chemistry and Neuroscience Center, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599-3290, USA
| | | | | | | | | | | |
Collapse
|
7
|
Benaliouad F, Kapur S, Rompré PP. Blockade of 5-HT2a receptors reduces haloperidol-induced attenuation of reward. Neuropsychopharmacology 2007; 32:551-61. [PMID: 16794561 DOI: 10.1038/sj.npp.1301136] [Citation(s) in RCA: 34] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
Abstract
Previous studies have shown that effective antipsychotic medications attenuate reward, an effect that is generally attributed to their effectiveness at blocking the dopamine D2-like receptors. As blockade of the serotonin type 2a (5-HT2a) receptors is a common property of the newer antipsychotics, the present study compared the effect of haloperidol, clozapine, and M100907 (a selective 5-HT2a antagonist) and the combined effect of haloperidol and M100907 treatment on brain stimulation reward (BSR). Experiments were performed on male Sprague-Dawley rats trained to produce an operant response to obtain electrical stimulation in the lateral hypothalamus. Measures of reward threshold were determined in different groups of rats using the curve-shift method using fixed current intensity and variable frequency before and at different times after injection of haloperidol (0.01, 0.05, 0.1, and 0.25 mg/kg), clozapine (1, 7.5, 15, and 30 mg/kg), M100907 (0.033, 0.1, and 0.3 mg/kg), or their vehicle. The effect of M100907 (0.3 mg/kg) on the attenuation of BSR by a sub- and suprathreshold dose of haloperidol was studied in another group of rats. Clozapine produced a dose-orderly increase in reward threshold with a mean maximal increase of 50%; at high doses, clozapine induced cessation of responding in several animals at different time periods. Haloperidol induced a dose-dependent increase in reward threshold, with the mean maximal increase (75%) being observed at the highest dose; it also produced a dose-dependent reduction of maximum rates of responding. M100907 failed to alter reward at any of the doses tested and had no effect on the subthreshold dose (0.01 mg/kg) of haloperidol. But when combined with a suprathreshold dose of haloperidol, M100907 reduced the reward-attenuating effect of haloperidol. These results show that 5-HT2a receptors are unlikely to constitute a component of the reward-relevant pathway activated by lateral hypothalamic stimulation. However, blockade of 5-HT2a receptors may account for the relatively lower level of reward attenuation produced by clozapine, and predict that antipsychotic medications that have a high affinity for the 5-HT2a receptor may be less likely to induce dysphoria.
Collapse
Affiliation(s)
- Faïza Benaliouad
- Centre de recherche Fernand-Seguin, Hôpital Louis-H Lafontaine, Montréal, QC, Canada
| | | | | |
Collapse
|
8
|
Desai RI, Neumeyer JL, Paronis CA, Nguyen P, Bergman J. Behavioral effects of the R-(+)- and S-(-)-enantiomers of the dopamine D(1)-like partial receptor agonist SKF 83959 in monkeys. Eur J Pharmacol 2006; 558:98-106. [PMID: 17207791 PMCID: PMC2447824 DOI: 10.1016/j.ejphar.2006.11.042] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/27/2006] [Revised: 11/16/2006] [Accepted: 11/21/2006] [Indexed: 11/18/2022]
Abstract
Dopamine D(1)-like partial receptor agonists such as SKF 83959 have been proposed as potential candidates for the treatment of cocaine addiction. The present studies were conducted to further characterize SKF 83959 by pharmacologically evaluating effects of its R-(+)- and S-(-)-enantiomers, MCL 202 and MCL 201, respectively, on overt behavior (eye blinking) and schedule-controlled performance in squirrel monkeys. MCL 202, like the D(1) full receptor agonist SKF 82958, produced dose-related increases in eye blinking and decreases in rates of fixed-ratio responding. However, the magnitude of effects of MCL 202 on eye blinking was less than observed with SKF 82958. In contrast to the effects of its R-(+) enantiomer, MCL 201 was relatively devoid of behavioral activity up to doses that were approximately 10-fold greater than MCL 202. Pretreatment with the selective D(1)-like receptor antagonist SCH 39166 dose-dependently antagonized increases in eye blinking produced by MCL 202, confirming the involvement of D(1) mechanisms in its effects. A dose-ratio analysis of the antagonism of effects of MCL 202 by SCH 39166 revealed an apparent pA(2) value of 7.675 with a slope of -0.78+/-0.04. In further studies, pretreatment with MCL 202 antagonized the effects of SKF 82958 on eye blinking and, like SCH 39166, schedule-controlled behavior in a dose-related manner. A dose-ratio analysis of the antagonist effects of MCL 202 on the SKF 82958-induced increases in eye blinking revealed ratios of 2.7, 4.8 and 31.1 for 0.1, 0.3 and 1.0 mg/kg dose of the antagonist, respectively, indicative of a significant change in the potency of SKF 82958. These results suggest that MCL 202, like its parent compound SKF 83959, has both D(1) receptor-mediated agonist and antagonist properties, consistent with its characterization as a partial agonist at the D(1)-like receptor. In addition, the inactivity of MCL 201, the S-(-)-enantiomer, suggests that the behavioral effects of SKF 83959 can be attributed primarily to the activity of its R-(+)-enantiomer.
Collapse
MESH Headings
- 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine/analogs & derivatives
- 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine/pharmacology
- Animals
- Behavior, Animal/drug effects
- Benzazepines/pharmacology
- Blinking/drug effects
- Conditioning, Psychological/drug effects
- Dopamine Agonists/pharmacology
- Male
- Receptors, Dopamine D1/agonists
- Saimiri
- Stereoisomerism
Collapse
Affiliation(s)
- Rajeev I. Desai
- McLean Hospital/Harvard Medical School, 115 Mill Street, Belmont, MA 02478, USA
| | - John L. Neumeyer
- McLean Hospital/Harvard Medical School, 115 Mill Street, Belmont, MA 02478, USA
- Brain Research Laboratories, Inc., 115 Mill Street, Belmont, MA 02478, USA
| | - Carol A. Paronis
- McLean Hospital/Harvard Medical School, 115 Mill Street, Belmont, MA 02478, USA
- Brain Research Laboratories, Inc., 115 Mill Street, Belmont, MA 02478, USA
| | - Phong Nguyen
- McLean Hospital/Harvard Medical School, 115 Mill Street, Belmont, MA 02478, USA
| | - Jack Bergman
- McLean Hospital/Harvard Medical School, 115 Mill Street, Belmont, MA 02478, USA
- Brain Research Laboratories, Inc., 115 Mill Street, Belmont, MA 02478, USA
| |
Collapse
|
9
|
Neurotoxins and medicinals for the treatment of Parkinson’s disease. Part 2: dopamine receptors and their agonists. Pharm Chem J 2005. [DOI: 10.1007/s11094-006-0014-x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/24/2022]
|
10
|
Bruijnzeel AW, Markou A. Decreased sensitivity to the effects of dopamine D1-like, but not D2-like, receptor antagonism in the posterior hypothalamic region/anterior ventral tegmental area on brain reward function during chronic exposure to nicotine in rats. Brain Res 2005; 1058:91-100. [PMID: 16126181 DOI: 10.1016/j.brainres.2005.07.056] [Citation(s) in RCA: 13] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/25/2005] [Revised: 07/26/2005] [Accepted: 07/27/2005] [Indexed: 01/17/2023]
Abstract
Chronic administration of nicotine induces adaptations in central nervous system function to counteract nicotine's acute effects. When nicotine administration ceases, these adaptations remain unopposed and may lead to drug withdrawal. The present studies were conducted to assess the effects of chronic nicotine administration on dopamine D1- and D2-like receptor activity in the posterior hypothalamus/anterior ventral tegmental area (VTA). An intracranial self-stimulation discrete trial procedure that provides current intensity thresholds was used to provide a measure of brain reward function in rats. Previous studies showed that systemic administration of dopamine D1- or D2-like receptor antagonists induced elevations in brain reward thresholds in drug-free rats, indicative of a decrease in brain reward function. We show here that injections of the D1-like receptor antagonist SCH 23390 (1-4 microg total bilateral dose) into the posterior hypothalamus/anterior VTA differentially elevated brain reward thresholds in rats chronically treated with nicotine (9 mg/kg/day, salt) versus saline-treated rats. The nicotine-treated rats were less sensitive to the threshold elevating effects of D1-like receptor antagonism. By contrast, the D2-like receptor antagonist eticlopride (1-4 microg total bilateral dose) injected into the posterior hypothalamus/anterior VTA significantly elevated brain reward thresholds in saline- and nicotine-treated rats. No differential effect of eticlopride on brain reward thresholds in saline- and nicotine-treated rats was observed. Decreased sensitivity to D1-like receptor antagonism in the posterior hypothalamus/anterior VTA may partly mediate the development of tolerance to the reinforcing effects of nicotine and the manifestation of negative affective signs associated with cessation of nicotine administration.
Collapse
Affiliation(s)
- Adrie W Bruijnzeel
- Molecular and Integrative Neuroscience Department, CVN-7, The Scripps Research Institute, La Jolla, CA 92037, USA
| | | |
Collapse
|
11
|
Choi KH, Clements RLH, Greenshaw AJ. Simultaneous AMPA/kainate receptor blockade and dopamine D2/3 receptor stimulation in the nucleus accumbens decreases brain stimulation reward in rats. Behav Brain Res 2005; 158:79-88. [PMID: 15680196 DOI: 10.1016/j.bbr.2004.08.010] [Citation(s) in RCA: 17] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/01/2004] [Revised: 08/16/2004] [Accepted: 08/16/2004] [Indexed: 11/24/2022]
Abstract
Interactions between dopamine (DA) and glutamate (GLU) in the mesocorticolimbic pathway of the brain may influence motivation and reward. Previous work from this laboratory has demonstrated that alpha-amino-3-hydroxy-5-methylisoxazole-4-propionic acid (AMPA)/kainate receptor blockade may potentiate decreases in exploratory motor activity induced by the DA D(2/3) receptor agonist 7-OH-DPAT in the nucleus accumbens septi (NAS). This study investigated the interaction of AMPA/kainate receptor antagonists CNQX or NBQX with 7-OH-DPAT on ventral tegmental area (VTA) brain stimulation reward (BSR). Effects of these compounds, alone and combined, were measured in male Sprague-Dawley rats stereotaxically implanted with a unilateral VTA electrode and bilateral guide cannulae in the NAS core or shell subregions. Rate-frequency analysis was used to assess BSR frequency thresholds and maximum response rates of rats trained to lever-press for reinforcing electrical stimulation. When given alone, CNQX (0.5 microg), NBQX (0.5 microg), or 7-OH-DPAT (5.0 microg) did not affect BSR frequency thresholds. Co-administration of CNQX or NBQX with 7-OH-DPAT synergistically increased BSR frequency thresholds, indicative of decreased reward. These data indicate that simultaneous AMPA/kainate receptor blockade and DA D(2/3) receptor stimulation in the NAS may act synergistically to inhibit motivated behaviours such as electrical brain self-stimulation.
Collapse
Affiliation(s)
- Kwang-Ho Choi
- Department of Psychiatry, NC6.524 University of Texas, Southwestern Medical Center, Dallas, TX 75390-9070, USA
| | | | | |
Collapse
|
12
|
Miguelez M, Bielajew C. Mapping the Neural Substrate Underlying Brain Stimulation Reward with the Behavioral Adaptation of Double-Pulse Methods. Rev Neurosci 2004; 15:47-74. [PMID: 15046199 DOI: 10.1515/revneuro.2004.15.1.47] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
Abstract
Behavioral adaptations of double-pulse methods--primarily collision and refractory period tests--have been employed to unveil the electrophysiological and anatomical characteristics of neural networks of known function. These paradigms are based on trade-off functions: a determination of different combinations of stimuli that yield the same behavioral output. A detailed explanation of the logic and methodology underlying these techniques is elaborated in this paper. The implementation of such approaches to the study of brain stimulation reward (BSR) has provided a means of discriminating between the neurons underlying this behavior from other cells activated by the stimulating electrode, endowing them with a particularly powerful scientific scope. An increasingly detailed portrait of the BSR substrate, both within and outside the medial forebrain bundle, has been emerging as a result of these investigations and is reviewed in this paper. Finally, the challenges associated with these paradigms are discussed and potential solutions as well as future experimental ventures proposed. Attention is drawn to the major contribution of these methods to our understanding of the neural pathways and characteristics underlying BSR.
Collapse
Affiliation(s)
- Maïa Miguelez
- School of Psychology, University of Ottawa, Ottawa, Ontario, Canada.
| | | |
Collapse
|
13
|
Abstract
The prefrontal cortex (PFC) has long been known to be involved in the mediation of complex behavioral responses. Considerable research efforts are directed towards refining the knowledge about the function of this brain area and the role it plays in cognitive performance and behavioral output. In the first part, this review provides, from a pharmacological perspective, an overview of anatomical, electrophysiological and neurochemical aspects of the function of the PFC, with an emphasis on the mesocortical dopamine system. Anatomy of the mesocortical system, basic physiological and pharmacological properties of neurotransmission within the PFC, and interactions between dopamine and glutamate as well as other transmitters within the mesocorticolimbic circuit are included. The coverage of these data is largely restricted to what is relevant for the second part of the review which focuses on behavioral studies that have examined the role of the PFC in a variety of phenomena, behaviors and paradigms. These include reward and addiction, locomotor activity and sensitization, learning, cognition, and schizophrenia. Although the focus of this review is on the mesocortical dopamine system, given the intricate interactions of dopamine with other transmitter systems within the PFC and the importance of the PFC as a source of glutamate in subcortical areas, these aspects are also covered in some detail where appropriate. Naturally, a topic as complex as this cannot be covered comprehensively in its entirety. Therefore this review is largely limited to data derived from studies using rats, and it is also specifically restricted to data concerning the medial PFC (mPFC). Since in several fields of research the findings concerning the function or role of the mPFC are relatively inconsistent, the question is addressed whether these inconsistencies might, at least in part, be related to the anatomical and functional heterogeneity of this brain area.
Collapse
Affiliation(s)
- T M Tzschentke
- Grünenthal GmbH, Research and Development, Department of Pharmacology, Postfach 500444, 52088, Aachen, Germany.
| |
Collapse
|
14
|
Baldo BA, Jain K, Veraldi L, Koob GF, Markou A. A dopamine D1 agonist elevates self-stimulation thresholds: comparison to other dopamine-selective drugs. Pharmacol Biochem Behav 1999; 62:659-72. [PMID: 10208371 DOI: 10.1016/s0091-3057(98)00206-8] [Citation(s) in RCA: 25] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
Abstract
The effects of the high-efficacy D1 receptor agonist SKF 81297 and the D2/3 receptor agonist 7-OH-DPAT on brain stimulation reward thresholds and on response latencies in responding for the stimulation, were compared to the effects of subtype-selective receptor antagonists and a dopamine uptake blocker. SKF 81297 produced dose-dependent elevations in reward thresholds but did not alter response latencies. In contrast, 7-OH-DPAT produced inconsistent reward threshold elevations, yet dose dependently increased response latencies. Both the dopamine D1 receptor antagonist SCH 23390 and the D2 antagonist raclopride elevated reward thresholds, but only raclopride significantly increased response latencies. The dopamine uptake inhibitor GBR 12909 lowered reward thresholds and did not influence response latencies. The present results provide a clear demonstration that a selective, high-efficacy D1 receptor agonist elevates brain stimulation reward thresholds without producing performance deficits. Furthermore, it was observed that the effects upon reward measures of D1-selective compounds, but not D2/D3-selective compounds, are dissociable from their effects upon response latency in this task. These results are discussed with regard to a distinction between the effects of indirect and direct dopamine agonists on reward thresholds, a distinction that does not depend upon the subtype-selectivity of the direct agonists tested.
Collapse
Affiliation(s)
- B A Baldo
- Department of Neuropharmacology, The Scripps Research Institute, La Jolla, CA 92037, USA
| | | | | | | | | |
Collapse
|